U.S. FDA Approves TECVAYLI® in Combination with DARZALEX… — JNJ +1.00 · News Impact Screener

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX… — JNJ +1.00 · News Impact Screener

Which stocks this story touches

How each ticker is affected

JNJ+1.00
More positive than 98% of ticker scores this week
Received FDA approval for TECVAYLI in combination with DARZALEX FASPRO, expanding its treatment options for RRMM.
HALO+1.00
More positive than 98% of ticker scores this week
The company's ENHANZE technology is central to the newly FDA-approved combination treatment for multiple myeloma.

Connected tickers

HALO→JNJpartner
+0.90
More positive than 79% of relationship scores this week
[mutual] Halozyme's ENHANZE technology is used in Johnson & Johnson's DARZALEX FASPRO.
HALO→BMYpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE technology is licensed to Bristol-Myers Squibb.
HALO→LLYpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE and Hypercon technologies are licensed to Eli Lilly.
HALO→PFEpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE technology is licensed to Pfizer.
HALO→ROGpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE technology is licensed to Roche.
HALO→TAKpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE technology is licensed to Takeda.
HALO→ABBVpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE technology is licensed to AbbVie.
HALO→ARNXpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE and Hypercon technologies are licensed to argenx.
HALO→MRNYpartner
+0.70
More positive than 39% of relationship scores this week
[mutual] Halozyme's ENHANZE technology is licensed to Merus N.V.
HALO→TEVApartner
+0.60
More positive than 18% of relationship scores this week
[mutual] Halozyme has ongoing development programs with Teva Pharmaceuticals.
HALO→VTRSpartner
+0.60
More positive than 18% of relationship scores this week
[mutual] Halozyme has ongoing development programs with McDermott Laboratories, an affiliate of Viatris Inc.